有效反流口面积与左室舒张末期容积比值对经导管二尖瓣修复结局的影响:COAPT试验二次分析
该研究为COAPT随机临床试验的事后二次分析,共纳入548例患者,评估有效反流口面积(EROA)、反流体积(RV)与左室舒张末期容积指数(LVEDVi)对经导管二尖瓣修复(TMVr)获益的影响。结果发现,与MITRA-FR入组特征一致的小亚组(n=56)在24个月全因死亡或心衰住院复合终点上无显著差异,但生活质量和6分钟步行距离显著改善;提示TMVr获益不完全支持比例-非比例假说。
要点
- COAPT中类MITRA-FR亚组24个月全因死亡或心衰住院无显著获益。
- 该亚组TMVr后12个月生活质量和6分钟步行距离显著改善。
- TMVr获益不完全支持比例-非比例假说。
核心结论
- 小部分类似MITRA-FR的COAPT患者未在24个月全因死亡或心衰住院上获益,但在生活质量和6分钟步行距离等患者中心结局上有显著获益。
- 进一步亚组分析提示TMVr的获益不完全支持比例-非比例假说。
研究设计与样本
- COAPT随机临床试验的事后二次分析,执行时间为2012年12月27日至2017年6月23日。
- 共纳入548例患者,分为与MITRA-FR入组特征一致的第1组(n=56)和其余COAPT患者第2组(n=492)。
- 干预为经导管二尖瓣修复(TMVr)联合最大耐受指南导向药物治疗(GDMT)对比单独GDMT。
临床怎么用
- 对于继发性二尖瓣反流患者,即使特征类似MITRA-FR,TMVr仍可能改善生活质量和运动耐量。
- 临床决策不应仅依据EROA与LVEDVi的比例关系判断TMVr获益。
局限性
- 为事后二次分析,亚组样本量小(第1组n=56),结果需谨慎解读。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Transcatheter mitral valve repair (TMVr) plus maximally tolerated guideline-directed medical therapy (GDMT) reduced heart failure (HF) hospitalizations (HFHs) and all-cause mortality (ACM) in symptomatic patients with HF and secondary mitral regurgitation (SMR) compared with GDMT alone in the Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation (COAPT) trial but not in a similar trial, Multicenter Study of Percutaneous Mitral Valve Repair MitraClip Device in Patients With Severe Secondary Mitral Regurgitation (MITRA-FR), possibly because the degree of SMR relative to the left ventricular end-diastolic volume index (LVEDVi) was substantially lower. OBJECTIVE: To explore contributions of the degree of SMR using the effective regurgitation orifice area (EROA), regurgitant volume (RV), and LVEDVi to the benefit of TMVr in the COAPT trial. DESIGN, SETTING, AND PARTICIPANTS: This post hoc secondary analysis of the COAPT randomized clinical trial performed December 27, 2012, to June 23, 2017, evaluated a subgroup of COAPT patients (group 1) with characteristics consistent with patients enrolled in MITRA-FR (n = 56) (HF with grade 3+ to 4+ SMR, left ventricular ejection fraction of 20%-50%, and New York Heart Association function class II-IV) compared with remaining (group 2) COAPT patients (n = 492) using the end point of ACM or HFH at 24 months, components of the primary end point, and quality of life (QOL) (per the Kansas City Cardiomyopathy Questionnaire overall summary score) and 6-minute walk distance (6MWD). The same end points were evaluated in 6 subgroups of COAPT by combinations of EROA and LVEDVi and of RV relative to LVEDVi. INTERVENTIONS: Interventions were TMVr plus GDMT vs GDMT alone. RESULTS: A total of 548 participants (mean [SD] age, 71.9 [11.2] years; 351 [64%] male) were included. In group 1, no significant difference was found in the composite rate of ACM or HFH between TMVr plus GDMT vs GDMT alone at 24 months (27.8% vs 33.1%, P = .83) compared with a significant difference at 24 months (31.5% vs 50.2%, P < .001) in group 2. However, patients randomized to receive TMVr vs those treated with GDMT alone had significantly greater improvement in QOL at 12 months (mean [SD] Kansas City Cardiomyopathy Questionnaire summary scores: group 1: 18.36 [5.38] vs 0.43 [4.00] points; P = .01; group 2: 16.54 [1.57] vs 5.78 [1.82] points; P < .001). Group 1 TMVr-randomized patients vs those treated with GDMT alone also had significantly greater improvement in 6MWD at 12 months (mean [SD] paired improvement: 39.0 [28.6] vs -48.0 [18.6] m; P = .02). Group 2 TMVr-randomized patients vs those treated with GDMT alone tended to have greater improvement in 6MWD at 12 months, but the difference did not reach statistical significance (mean [SD] paired improvement: 35.0 [7.7] vs 16.0 [9.1] m; P = .11). CONCLUSIONS AND RELEVANCE: A small subgroup of COAPT-resembling patients enrolled in MITRA-FR did not achieve improvement in ACM or HFH at 24 months but had a significant benefit on patient-centered outcomes (eg, QOL and 6MWD). Further subgroup analyses with 24-month follow-up suggest that the benefit of TMVr is not fully supported by the proportionate-disproportionate hypothesis. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01626079.
引用
- Lindenfeld J, Abraham WT, Grayburn PA, et al. Association of Effective Regurgitation Orifice Area to Left Ventricular End-Diastolic Volume Ratio With Transcatheter Mitral Valve Repair Outcomes: A Secondary Analysis of the COAPT Trial. JAMA Cardiol. 2021. PMID: 33533873. doi:10.1001/jamacardio.2020.7200
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。